Program
LP-98
A development code. Also written as “LP-98 injection”, “Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.” and “LP-98 20 mg”.
Its studies are mostly in Acquired Immunodeficiency Syndrome, led by Shanxi Kangbao Biological Product.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanxi Kangbao Biological Product | 31 open or running | phase 2since Aug 15, 2024 | Jun 27, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 27, 2023First study: phase 1 study in Acquired Immunodeficiency SyndromeFirst studyNCT05933824 · 36 enrolled · China
- Aug 15, 2024Phase 2 study in Acquired Immunodeficiency SyndromeNCT06560489 · 40 enrolled · China
- Feb 5, 2026Phase 2 study in HIVNCT07433387 · 30 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07433387HIV · China | 2 | Recruiting | Jul 10, 2026 | 30 |
| NCT06560489Acquired Immunodeficiency Syndrome · China | 2 | Completed | Jan 10, 2025 | 40 |
| NCT05933824Acquired Immunodeficiency Syndrome · China | 1 | Completed | Apr 12, 2024 | 36 |
How it is read
Names in the registry
- “LP-98 injection”, 1 entry
- “Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.”, 1 entry
- “LP-98 20 mg”, 1 entry
- “LP-98 40 mg”, 1 entry
- “LP-98 80 mg”, 1 entry
Codes read as this program: LP98.
Conditions, from the studies’ own filings
- Acquired Immunodeficiency Syndrome, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.